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M
itosis is a fantastically com-
plex process, but the simple 
beauty of chromosome segre-
gation can captivate even the untrained 
eye. When Angelika Amon saw a video of 
a dividing cell as a schoolgirl in Austria, 
it set her on a path to a professorship at 
the Massachusetts Institute of Technology 
in Cambridge, MA, where she continues 
to investigate chromosome segregation 
and the consequences of mitotic errors.
Amon began her research career as a 
PhD student with Kim Nasmyth at the Insti-
tute of Molecular Pathology in Vienna, 
studying how cyclin levels are controlled 
over the course of the budding yeast cell 
cycle (1). After a brief postdoc with Ruth 
Lehmann at the Whitehead Institute in Cam-
bridge, MA, Amon was offered the chance 
to start her own lab at the institute as a 
Whitehead fellow. She returned to studying 
the yeast cell cycle, identifying some of the 
key proteins that trigger cyclin degradation 
and mitotic exit (2, 3). Since joining the 
MIT faculty, Amon has con-
tinued to investigate how one 
of these proteins—Cdc14—
is regulated (4, 5), while also 
studying how the basic mi-
totic machinery is adapted 
for the two sequential divi-
sions of meiosis (6). More 
recently, Amon has turned 
her attention to the consequences of aneu-
ploidy—abnormal numbers of chromo-
somes due to segregation defects—and its 
potential links to tumorigenesis (7, 8). In a 
recent interview, we spoke with Amon about 
her passion for cell division and where her 
research is heading next.
ENTERING THE CELL CYCLE
Where did you grow up?
I grew up in Vienna, Austria. I was always 
interested in science—I wanted to study 
dinosaurs when I started school, and then 
I wanted to be a zoologist for a long time. 
But when I was in high school, I saw some 
old chromosome segregation movies—
black and white ones from the ’50s. I 
thought it was the coolest thing ever, and 
I still do. Seeing the sister chromatids 
split takes your breath away. Most people 
have the same reaction. I now go to my 
children’s schools to talk about being a 
scientist, and I always show them that 
movie. Even the youngest children appre-
ciate that this is something special.
That interest in cell division led to 
you joining Kim Nasmyth’s group for 
your PhD…
Yes, and he was a fantastic teacher. Kim is 
probably one of the clearest thinkers of our 
time. Being in his lab was a remarkable ex-
perience, and I had the great privilege of 
being taught by Kim himself. He was still 
working in the lab, and my bench was next 
to his, though that wasn’t always easy!
I studied how cyclins are confi  ned to 
the right stages of the yeast cell cycle. First, 
I showed that there is some intricate feed-
back between the different cyclins at the 
transcriptional level. Then I 
showed that ubiquitin-medi-
ated cyclin degradation is 
important for mitotic exit 
and that this degradation 
persists through G1 until it’s 
turned off as cells enter the 
next cell cycle. That had an 
important practical implica-
tion because we could arrest cells at a stage 
where cyclins were continually degraded 
and look for mutants that could no longer 
degrade them. This allowed another postdoc 
in Kim’s lab to identify genes required for 
cyclin degradation, which led to the identifi  -
cation of the anaphase-promoting complex.
Initially, you took a different direction 
for your postdoc and joined Ruth 
Lehmann’s lab to work on Drosophila 
germ cell development…
Yes, and I still think she’s one of the most 
wonderful scientists around today. It’s just 
that fl  ies weren’t for me. Though I was great-
ly attracted to the genetics of Drosophila, 
everything had to be done in such a rounda-
bout way at that time. What’s so incredible 
about working in yeast is that the rate-lim-
iting step is your brain. You can do anything 
you can think of very cleanly and precisely. 
But after two years, Ruth left for New York, 
and I got the wonderful opportunity to be-
come a Whitehead fellow and start my own 
independent research group.
RECYCLING TO CYCLINS
Did you consider doing another postdoc 
with somebody else instead?
I did think about it. I was unsure about 
this decision until I realized that it was a 
great opportunity to see whether I could 
run a lab on my own. I thought that, if I 
failed, at least I would have found out ear-
lier that I was no good at it, without wast-
ing four years as a postdoc.
In hindsight, it was truly the best thing 
that ever happened to me. The Whitehead 
fellows program is really good for women 
because it allows you—at a relatively early 
age—to do science without having to 
spend 15 hours a day in the lab. You have 
a technician or maybe a postdoc to do a 
good fraction of the experiments. I was 
really lucky to have two gifted and moti-
vated women work with me, so I was able 
to have my fi  rst child at the age of 31. For 
a scientist, that’s young. I really believe 
this type of fellowship is the best way to 
promote women in science.
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Amon studies how cells segregate their chromosomes and what 
happens when they get it wrong.
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As a Whitehead fellow, you returned to 
working on the budding yeast cell cycle…
The fi  rst thing we did was to discover that 
Cdc20 and Cdh1 activate the anaphase-
promoting complex. That was an important 
discovery for the fi  eld. But I realized that 
the Xenopus biochemistry labs were in a 
much better position than us to fi  gure out 
the mechanism. So, I made a conscious 
decision not to pursue this any further.
Instead, we started to investigate how 
cyclin degradation was triggered during 
mitotic exit. That was completely unclear 
at the time. We had developed a number of 
assays to look at cyclin destruction, and we 
screened candidates from Lee Hartwell’s 
original Cdc collection. Cdc14 looked the 
best, and it turned out to be very important 
for mitotic exit in budding yeast.
We’re still very interested in how Cdc14 
is regulated. A few years ago, we discov-
ered that a checkpoint that senses whether 
the spindle is positioned correctly regulates 
Cdc14 via a GTPase signaling pathway 
called the mitotic exit network. We still 
need to understand the details of this spa-
tial control of mitotic exit. But there’s a 
temporal control, too—Cdc14 activation is 
restricted to anaphase, and we really don’t 
understand at all how that works.
You also work on meiosis. What interests 
you about this type of cell division?
We’re interested in how the basic cell cycle 
machinery is changed by meiosis-spe-
cific factors—how the ki-
netochore is altered so that 
sister chromatids co-orient 
toward the same spindle pole 
during the fi  rst meiotic divi-
sion, and how sister chro-
matid cohesion is regulated 
differently during meiosis. 
More recently, we’ve also be-
gun to study how a cell de-
cides to enter meiosis. What 
triggers the decision to become a germ cell? 
It’s a very poorly understood process.
WHEN MITOSIS GOES BAD
A few years ago, you started to work on 
aneuploidy. How did that come about?
We always write in our grants that we need 
to understand chromosome segregation 
because when cells mis-segregate chro-
mosomes, they become aneuploid and 
this causes cancer. But we don’t really 
know if that’s correct. It’s true that the 
vast majority of tumors are aneuploid, but 
we don’t know what aneuploidy does to 
cells. At the organismal level it’s clear 
that aneuploidy is detrimental. An extra 
chromosome is frequently lethal or causes 
severe problems in all species where this 
has been analyzed. As a yeast geneticist, 
you’ll sometimes get a chromosome mis-
segregating during a cross, and that invari-
ably makes the yeast cell sick. But in the 
context of cancer, aneuploidy is associated 
with high proliferative potential.
Something doesn’t chime there, and we 
thought that the only way we could under-
stand it was to fi  rst determine what the ef-
fects of having an extra chromosome are on 
a normal, untransformed cell. Then we can 
ask how, if at all, this contributes to cancer.
What effect does aneuploidy have 
on cells?
It stresses them. It turns out that these extra 
chromosomes are active in yeast, mice, and 
humans, and they produce transcripts and 
proteins. These extra proteins can have spe-
cifi  c  effects—-tubulin, for example, is 
very toxic when it’s overexpressed. But our 
data suggest that there are also more gen-
eral effects that cause proteotoxic stress. 
Extra proteins might lead to partially assem-
bled complexes, and cells really don’t like 
that. There are only a limited 
number of ways for a cell to 
deal with these extra proteins, 
using either the proteasome 
or the chaperone system. So 
even though, depending on 
the aneuploid chromosome, 
the proteins causing the prob-
lems are different, they put 
stress on the same pathways 
in all cells.
Now the question is: can we identify 
mutations that suppress these adverse 
effects? Such mutations might be im-
portant during tumor evolution, because 
they would allow aneuploid cells to grow 
better. We also want to look for synthetic 
lethality—perhaps we can fi  nd ways to 
preferentially kill aneuploid cells.
Is mis-segregation just something that 
cancer cells have to mitigate, or are 
there actual beneﬁ  ts to aneuploidy?
I think there is a lot of evidence to sug-
gest that even though aneuploidy, per se, 
is bad for cells, it can be benefi  cial in 
specific circumstances. There was a 
beautiful study from Judith Berman’s lab 
that looked at antifungal resistance in 
yeast. Duplicating a region of chromo-
some 5 that encodes ERG11, the target 
of the antifungal drug, and TAC1, a tran-
scriptional regulator of drug effl  ux 
pumps, allowed the yeast to grow better 
in the presence of the antifungal agent, 
even though the cells grew poorly under 
normal growth conditions. So maybe 
during  metastasis, for example, aneu-
ploidy could be benefi  cial and help can-
cer cells to conquer a new niche.
There are still lots of things we want to 
understand in this area, but I’m always 
looking for new things. I’ve decided I 
need to work on how mitochondria talk to 
the nucleus. I think that’s an interesting 
question. I wish I had 60 people in the lab, 
and then we could do all these things!
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A metaphase spread from mouse B cells shows 
trisomy for chromosomes 5 and 14.
“At the 
organismal 
level it’s 
clear that 
aneuploidy is 
detrimental.”